Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 18 years or older with body weight \>40kg~* Written informed consent~* Presented within 48 hours of onset of influenza-like illness~* Presumptive diagnosis of H1N1 satisfying the following clinical and laboratory criteria:~  * Clinical criteria~    * Fever \>38 oC (Infrared Forehead Thermometer will be used to measure the Temporal Artery Temperature under the skin) AND~   * At least one upper respiratory tract infection (cough, running nose, sore throat)~ * Laboratory criteria Positive rapid test result for influenza A (by Influenza Rapid Diagnostic test) within 48 hours of onset of flu-like symptoms~Exclusion Criteria:~* Age below 18 years~* Persons who lack the ability to care for themselves~* Patient with critical condition or already developed severe respiratory distress with hypoxaemia on presentation~* Pregnancy or lactation~* Coexisting liver disease~* Coexisting cardiovascular disease except stable hypertension without complication~* Coexisting chronic pulmonary disease~* Coexisting immuno-compromised medical conditions or on concurrent immunosuppressive therapies~* Renal failure~* Terminal malignancies or terminal end-organ failure with an estimated life-expectancy of less than 3 months~* Known intolerance to oseltamivir or zanamivir~* Known history of significant neurological disorders that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration or those~* Subjects who have received oseltamivir as prophylaxis for H1N1 infection~* Subjects who have received any investigational drug within 1 month prior to study entry~* Subjects with a mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oseltamivir (Type: EXPERIMENTAL): None
- Zanamivir (Type: EXPERIMENTAL): None
- Placebo of Oseltamivir (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).